Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD

NAActive, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 4, 2023

Primary Completion Date

February 10, 2024

Study Completion Date

March 29, 2024

Conditions

Hypertension, PulmonaryLung Diseases, Interstitial

Interventions

DEVICE

Inhaled Nitric Oxide (iNO)

eNOfit system delivering iNO

Trial Locations (3)

Medical University of South Carolina, Charleston

TGH/USF Center for Advanced Lung Disease and Lung Transplant, Tampa

University of Cincinnati, Cincinnati

All Listed Sponsors

lead

Third Pole Therapeutics, Inc.

INDUSTRY

NCT05867914 - Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD | Biotech Hunter | Biotech Hunter